Hims & Hers Health, Inc. (HIMS) on Q3 2021 Results - Earnings Call Transcript
Operator: Good afternoon and thank you for joining us today’s Conference Call to discuss Hims & Hers Health, Inc.’s Third Quarter 2021 Financial Results. Joining me on today's call are Andrew Dudum, our Chief Executive Officer; and Spencer Lee our Chief Financial Officer. On this call, we will be making forward-looking statements, including the financial guidance and expectations for our fourth quarter 2021 and fiscal year 2021 and 2022 growth, expansion into new categories, strategies, customer demand and products. These statements reflect our best judgment based on the factors currently known to us as the actual events or results may differ materially. Please refer to the documents that we file with the SEC including the Form 8-K filed with today's press release. Those documents contain risks and other factors that may cause our actual results to differ from those contained in our forward-looking statements. These forward-looking statements are based made as of today and we will discuss -- disclaim any obligations to update or revise these statements. If this call is reviewed after today, the information proceeding during this call may not be current or accurate. We will also discuss the non-GAAP financial measures, which are not prepared in accordance with the general accepted accounting principles. For the historical periods, the reconciliations with GAAP and non-GAAP results are provided in the press release filed today with the SEC on an 8-K and also available on our website. And with that I'll now turn the call over to Andrew Dudum. Andrew Dudum: Welcome and thank you all for joining our Q3 earnings call. This quarter was yet again another quarter where our team's execution was outstanding. Our mission is to make the highest quality personalized healthcare accessible to everyone. This quarter we delivered on that mission at a scale never achieved in the company's history. Across the board, we exceeded our guidance with revenue coming in at over $74 million representing 79% year-over-year growth. Subscription members the underlying driver of our subscription business grew 95% year-over-year to over 500,000. This outperformance across the spectrum was driven by continued robust growth in our core Hims categories where our entrenched brand and trusted products continue to deliver exceptional growth as well as continued acceleration in our newest expansion categories such as mental health growing 1,000% year-over-year. Our fundamentals underpin what I continue to believe is an exceptionally rare opportunity in the public market a beloved consumer brand that is built upon an enduring subscription membership business model. Approximately, 94% of our GAAP revenue was recurring subscription revenue made possible by robust 88% long-term revenue retention. Hims & Hers brings together the best of high-growth consumer Internet coupled with the fundamental economics of enterprise SaaS. We believe what we are delivering is different from anything in the market and our brand approach and execution continues to deliver real durable competitive advantages. While Spencer will spend more time reviewing the quarter in his remarks, I wanted to take the majority of the time today to share what I believe is the most exciting news of the day. Today, we launched our mobile platform and plan to roll it out fully over the coming weeks and months to over 500,000 Hims & Hers members. To me this marks one of the most exciting launches in our company's history as we continue to further advance our goal of fundamentally reshaping what it will mean to access and experience great modern healthcare. I believe that the launch of our mobile platform is significant not just for our company, but for the industry as a whole. The Hims & Hers mobile platform is a major step in visualizing the radically different vision we have for the future of health and wellness. Our members grew up expecting innovative, digitally native and all-inclusive experiences like Spotify, Netflix and Peloton. Those companies structurally changed the fundamental business models of their traditional industry in favor of everyday consumer experiences. We believe the healthcare industry is in need of that structural change as well and we view today's launch as a major step toward Hims & Hers building that future. We imagine a world where the hardest part of accessing treatment options for a health challenge is pushing play on a guided and integrated program, a program led by inspiring and compassionate coaches, backing partnership by leading medical institutions and specialists that brings together streamlined education, original content, community support, treatment and oversight. We imagine a world where hundreds of programs are available at your fingertips from helping track and improve your cholesterol to navigating the complexities of IVF with their partner. We imagine a world where the concept of scheduling an appointment, coordinating a visit, finding a specialist or asking about even the smallest health concern is as simple as texting your concierge, who not only knows your name, but ensures someone is available to you 24/7 on call to assist you. We anticipate that our mobile platform will be the foundation on which we build and invest in this future further bundling additional value for our members. It is hard to overstate the potential and full extent of how broadly we're thinking about this opportunity over the long-term. In the near term, I'm confident what we built will be wildly additive to our existing offerings. In the long-term, I believe we may have just introduced a new way entirely to think about the delivery of healthcare. We're excited to continue pushing the boundaries on behalf of everyday people, unconstrained by the existing entrenched systems of today and focus solely on how to empower the masses with beautiful, affordable and accessible care. For all of you visual learners, we've created a destination to see the core experiences within the mobile app. Let me walk you through a few of those core aspects. And for anybody interested feel free to follow along more visually at the URL app.forhims.com. To begin, let me introduce you to programs. Programs provide consumers with beautiful and fun original content journeys for a range of curated health challenges. Programs are led by energetic and compassionate coaches aiming to help each customer move along their journey of improved health. In partnership with leading medical experts and specialists, each program has been crafted to provide a world-class educational journey at the click of a button. Programs are a new world of access and community for people struggling to take the first step in resolving a health or wellness challenge. We believe programs have the potential to help millions of people take that first step. From helping reduce anxiety and resolve hormonal acne, to sleeping better or navigating fertility challenges, we believe programs are an innovative new form factor that will help bring to the masses the best medical expertise. This is a new platform for us, which we will be building and creating on top of for years to come. Second, let me introduce you to care. Hims & Hers members will now have full access to care, a simple and unified hub for accessing your entire virtual care team. Within care, customers will have access to support in a variety of ways, from scheduling consultations, with licensed medical professionals on video, phone or chat to leveraging unlimited messaging access to the medical experts that are supporting their treatment plans. Within care, members will also find our new 24/7 concierge, where members will have around the clock access to highly trained coordinators helping navigate the ecosystem, coordinate with their virtual care team or simply help get the answers you need regarding your treatment plan. And lastly, introducing the member store. The member store is expected to bring together the entirety of the Hims & Hers product portfolio into one, simple and personalized space. Consumers will soon have one clickability to purchase at member pricing some of our most highly rated over-the-counter health and wellness offerings. From supplements to support sleep, to products tackling hair loss, the member store allows for curated and personalized offerings bundled for easy access to up level daily routines or enhance current plans. While still early, we believe that what we are building envisions a new future in healthcare, a single entry point into a beautiful healthcare world, simplifying the complexity of feeling great and being well. I'm so proud of the team for what they've drummed up, and have executed upon. Today, our business is stronger than it has ever been. We added more members to our platform in Q3 than any quarter in our company's history. Our products line the shelves at nearly 10,000 physical brick-and-mortar locations nationwide, including most recently a nationwide rollout in Walgreens. From the loyalists of JLO, and the irreverent lovers of Miley Cyrus, to the Sunday night fans of Rob Gronkowski, Hims & Hers is everywhere, an omni-channel strategy to build the first true consumer healthcare brand. Enhanced by this brand, our platform capabilities are only growing. And with this latest mobile platform, we feel confident in our abilities to lead in innovating, visualizing and ultimately creating the future of healthcare. I've said this before, but I feel it's worth repeating, we are a company passionate about building this future. We pride ourselves on being visionary in our sector, sustaining consistent execution and delivering growth, and I feel this quarter is highly reflective of our ability to be the leader in this space. I'm proud of the results we shared with you today and of our team's dedication to our mission. At this point, I will now turn the call over to Spencer for a more detailed review of our results followed up by Q&A. Spencer Lee: Thank you, Andrew. I'm pleased to report, another incredibly strong financial quarter for Q3. I'll walk through the details behind our performance for the quarter then discuss our revised upwards guidance for Q4. First, let's discuss our Q3 results. In addition to continuing to drive strong growth in both the Hims & Hers brands, we also began integrating the company's first two acquisitions Apostrophe and Honest Health, with both companies on track with integration and go-to-market expectations. Q3 was a quarter with many moving parts. And with this additional complexity on our last earnings call, we not only provided guidance for revenue and adjusted EBITDA for Q3, but we also discussed several other metrics, including gross margin, marketing, expense and AOV. I'm pleased to report that, we met or exceeded our guidance across every metric we provided on our previous call. In Q3, we generated revenue of $74.2 million, up 79% year-over-year, which exceeded the high end of our revenue guidance of $71 million. Q3 included approximately $5 million from Apostrophe, which was at the high end of the guidance we provided. Our strong growth this quarter continues to demonstrate the deep underserved demand of a new generation of experience-driven and brand savvy healthcare consumers. Our ability to identify these audiences and deeply connect with them through our brands and drive engagement and conversion to our unique digital experiences resulted in Q3 subscriptions growing 95% year-over-year to approximately $551,000. We generated nearly one million net orders in the quarter 968,000 to be precise, which accelerated to 66% growth year-over-year. Year-over-year growth in net orders has accelerated for the last four consecutive quarters, which we believe further demonstrates the deep consumer demand that exists in the market and our unique ability to capture it. Q3 gross margin was 74% and in line with the guidance we provided last quarter. As we indicated on our previous earnings call, the quarter-over-quarter decrease in gross margin was primarily driven by lower margin revenue from Apostrophe and Honest Health. As we continue to integrate, our teams and capabilities, we see opportunities for margin expansion for both acquisitions over the medium-term. Q3 marketing expenses were $38 million, right in line with the guidance we provided last quarter. Q3 marketing expenses included the marketing budgets we inherited from Apostrophe and Honest Health, and the upfront investments we made for our celebrity partnerships with Miley Cyrus and Rob Gronkowski. We are exceptionally pleased with the continued performance and scalability of our marketing. What we've been able to accomplish this year with our marketing efforts, I think has been really special and quite unique. Like many, we've seen ad rates increase throughout the year. Yet in the face of these rate increases, we have kept our acquisition cost per new subscriber effectively flat the entire year. From Q1 to Q3, the variance between our highest CAC quarter and lowest CAC quarter has been less than 3%. Another way of saying this is that CAC has essentially been flat all year. Keeping CAC flat in an environment of increasing rates would be impressive by itself. However, we've done this while also scaling subscriptions and exceeding our revenue targets. Often when ad rates increase, companies are forced to make the tough choice between maintaining tax by spending less and having growth decline or increasing marketing spend at ever-increasing marginal tax in order to hit growth targets. This is why I think our execution has been so special and unique. Not only have we been able to hold our tax flat this year, we've done so while also growing revenue 79% year-over-year and subscriptions 95% year-over-year in Q3. Throughout the year, we've discussed the underlying drivers of our efficient marketing performance but I want to take a moment to really emphasize them. First, we have a diversified marketing model but we are not dependent on any single marketing channel to drive growth. Since the start of the company, we have tested and learned how to scale and drive growth from a broad range of marketing channels including digital and offline channels. In Q3, no single marketing channel accounted for more than 25% of total marketing expenses. This expertise and diversification allow us to continuously allocate our budget to the highest performing channels to drive efficiency and growth. Second, our data and analytics capabilities allow us to deeply understand our core audiences, develop assets and campaigns that drive high engagement and allow us to very effectively identify, target and convert, high intent and high-value consumers. These capabilities have allowed us to exceed our targets for revenue and growth throughout the year, including in Q3, despite price fluctuations across channels. Adjusted EBITDA loss in Q3 was $9.8 million in line with guidance. We made several investments this quarter that we expect to provide future tailwinds including the upfront marketing expenses associated with our Miley Cyrus and Rob Gronkowski partnerships, the close of the Apostrophe acquisition in July and continued investments in people and capabilities across our core business and new categories. Now moving on to financial guidance. For Q4 2021, we are raising our revenue guidance to a range of $76 million to $78 million. This includes approximately $2 million from our new wholesale agreement with Walgreens. Excluding Walgreens, we're guiding to a Q4 revenue range that is roughly in line with Q3 revenue. We've provided this guidance that Q4 revenues would be in line with Q3 for the last seven months starting on our earnings call in May. We are reiterating this guidance as it reflects our run rate of Q4 trends and the uncertainty around seasonal ad markets, particularly in light of what we observed last year. I also want to note that we expect gross margins to sequentially decline by approximately two points in Q4, driven by a higher mix of wholesale revenue from Walgreens and increased seasonal shipping costs that have been indicated by our shipping carriers. We expect full year revenue of $263 million to $265 million, implying 77% year-over-year growth at the midpoint. For Q4, adjusted EBITDA loss we are guiding to a range of $12 million to $14 million. For the full year, we continue to narrow the range to an adjusted EBITDA loss of $35 million to $37 million. And finally, as we are working on our plan and budget for 2022, I wanted to provide some thoughts about next year. In October 2020, we shared an investor presentation during our SPAC process that provided revenue growth projections of 30% for both 2021 and 2022. We've completely outstripped our growth projections for 2021. We're currently guiding to $264 million in revenue at the midpoint for 2021, growing 77%, beating our previous projection by $85 million. However, our revenue projections from last October are instructive on how management views the long-term growth prospects of the company. But we believe we are addressing numerous multibillion-dollar markets that we are uniquely positioned to address this new generation of healthcare consumers with a brand and set of experiences to meet their needs and that we are well positioned to be a long-term high-growth business. As we finalize our plans, we expect to provide formal guidance for 2022 on our next call. As we close out this incredibly strong year, we thought it would be worthwhile to share that we continue to feel good about a 30% revenue growth rate for 2022. Before I pass the call back to the operator, I wanted to quickly reflect on 2021. We continue to be an exceptionally fast growing company, guiding to a 77% revenue growth this year, which is basically maintaining our 80% growth rate from last year. We are growing at this rate while on track to generate well over $250 million in revenue this year, reaching this incredible scale in roughly our fourth year of operation. On our first earnings call as a public company this past March, we guided to a full year adjusted EBITDA loss of $35 million to $45 million. We've continued to converge on the low end of this original range every quarter, while continuously exceeding our revenue estimates. Our current adjusted EBITDA guidance for the year means, we are losing on average only about $3 million per month, which seems very reasonable, given our exceptional growth, impressive scale and the fact that we have over $250 million in cash and investments on the balance sheet. 2021 is turning out to be an unbelievably strong year. I couldn't be more proud of what we've achieved. Operator, I'm happy to open up the call for questions. Operator: For our first question, we have Jailendra Singh from Credit Suisse. Jailendra, your line is open. Adam Heussner: Hi. This is Adam on for Jailendra today. Thanks for taking the question and congrats on the quarter. Just a quick follow-up on the Walgreens contribution in 4Q with this $2 million of expected contribution. Going back to what was going on with Target I know there were some many one-time in-store marketing and advertising benefits that the Target deal had? Is that a similar dynamic towards Walgreens? And I guess -- how should we expect that to transition in 2022 as the partnership kind of rolls off the early transition? Spencer Lee: Nothing to speak of right now in terms of special marketing arrangements with Walgreens, particularly not for Q4. I think, for Q4 in particular, with the Walgreens agreement, the POS that we've received for Q4 are actually only for a subset of the product assortment that will ultimately be in Walgreens. So next year, I think we can expect to see higher volume POS than what we've seen in Q4 as the full assortment rolls out over the course of next year. Adam Heussner: Got it. That’s very helpful. And then maybe just within this mobile app. Obviously, very exciting there to have rolled that out. It's just -- can you touch on how you're thinking about this platform in terms of retention on existing members, as well as just serving as a jumping off point for additional solutions around other areas of care that you might be looking to enter into in the future? Thanks. Andrew Dudum: Thanks, Adam. I think the mobile app is exactly focused on those two things, right? It's a platform and a home base for our over 0.5 million monthly subscription members. And so, part of that really lives in this care and programs world where it's guided handheld journeys and original content to better engage activate and make sure that these patients are getting the right clinical outcomes and then, also give them access to that 24/7 concierge experience where they have essentially a doctor in their pocket, right? And so I think that high-touch concierge experience and I would say focus on the clinical efficacy is really at the core of this. And so we do believe it has really material potential to impact retention long-term. When you look at retention for this business as Spencer and I have shared, there's incredible long tail, right, 88% long term retention. But most of that churn really takes place in the first couple of months of the consumer and patient getting acquainted with their medication and building that habit and building the daily process and experience of taking that regimen. And so, this world of these programs we think are a phenomenal innovation frankly in bringing healthcare to consumers in a digestible way, that is just going to make the engagement so much higher. So really excited about the impacts it could have for those 500,000 numbers. And then also just really excited for what it means for the future, right? You can imagine a world very naturally when you take a look at programs where there are literally hundreds of programs. And so, when we talk about the front door of healthcare system, this visually is a representation of that quite literally, right? You can imagine scrolling through a category for heart health and clicking a button to start a program around understanding your cholesterol levels, understanding where you sit and whether or not something like improved diet or a statin is appropriate for you. You can imagine the whole fertility section, right, for people who are trying to navigate IVF or adoption. So I think it's a foundation that really changes our ability to build innovation for consumers. And so, in that way, when you're talking about cross-sell when you're talking about customers better understanding what lives and it's bundled in your experience as a member, the ability to explore, the ability to one-click purchase. All of those things are enhanced dramatically in this type of a world. And so, we think this is arguably one of the most important things we've probably ever built as a company, in that, it's really going to be the foundation of what we continue to build on over the next five and 10 years. Adam Heussner: Great. Thanks and congrats again. Andrew Dudum: Thank you. Operator: For our next question, we have Daniel Grosslight from Citi. Daniel, your line is open. Daniel Grosslight: Hi, guys. I’ll add my congrats to the quarter. Great to see the results. I understand you're not formally guiding for 2022, but the 30% growth does imply a pretty steep step down to the growth that you saw in 2021, which admittedly was not anticipated. So I'm curious, was there some pull-through in 2021 from 2022? Is that just conservatism at this point in the year? How should we think about some of the drivers of 2022? Spencer Lee: Yes, sure thing. Hey, Daniel. So, yes, I mean, I think if you look back to our October presentation from 2020, obviously, for 2021 we've blown way past the revenue forecast that we provided for 2021. And again, as I mentioned, I think the 30% growth rate that we provided during the SPAC process are instructive in understanding management's perspective, right, that these -- that we are addressing massive multibillion-dollar markets that we have a unique set of experiences and brand that is resonating with this underserved new generation of healthcare consumers. And I think, with the 30% growth that we are, in some way, reaffirming here, our confidence in for 2022, is just a signal around our continued conviction at the size of these markets with the resonance of our brand and how underserved these audiences are and our unique ability to address these audiences. And at a 30% growth rate for next year, I mean, that means we'd be adding up to $80 million of additional revenue next year against our current 2021 guidance. And so, an additional $80 million of revenue, I think, further signals our confidence in the size of the markets and just the strong demand that exists out there. Daniel Grosslight: Yes. That makes total sense. Okay. And we've heard a lot about labor cost issues on the provider side more recently. I'm curious -- obviously, it's not showing up in your gross margin currently. But as you look ahead and lay out your kind of hiring plans or contracting plans on the provider side, have you noticed anything in terms of wages that you need to pay or shortages, particularly as you have seen so much growth in the mental health side of the business, which tend to have the most shortages out there? Andrew Dudum: Thanks, Daniel, for your question. Yes. We really haven't seen any material adjustments or necessity to change contracting or wages or pay in aggregate across the provider groups. And I think a big part of that is, frankly, when you talk to the physicians on our platform, right -- I think at this point it's over 300 to 400 physicians, they really truly enjoy practicing on the platform. And I think it's because it's a completely new first-generation technology build. It's a digitally native and mobile experience for a lot of them. These people are interfacing with beautiful technology to treat their patients and have that flexibility to do it as they are walking their dog right around their block. And so, I think the systems we've built, the technology and the interfaces that they are using, when they come to practice on the Hims & Hers platform is actually just really energizing and makes their like seamless. And so, we've had really no massive changes or no material difficulties in the hiring recruiting or retaining of the provider groups. And that's really been the case since the beginning. But I frankly think that's likely the realities on a go-forward basis as well. Daniel Grosslight: All right. Good to hear. Congrats again on the quarter. Andrew Dudum: Thank you. Operator: And for our next question we have Michael Cherny from Bank of America. Michael, your line is open. Unidentified Analyst: Hi. This is Charlotte on for Mike, and thanks for taking my question, and congrats on the quarter. My first question was just around updates on category expansion. I know in the past you've called out, doubling the number of categories you're in by 2025. If you could just provide any color here on the steps you're taking? And what really seems to be top of mind? Andrew Dudum: Yeah. Thank you so much for your question. I think we've definitely shared that this business is scaling exceptionally quickly because of the unique ability to both build a grant and execute on expansion categories, right? So, as we mentioned previously in the re-recorded transcript mental health is growing as 1,000% year-over-year, right? So these dynamics are really contributing to very meaningful revenue and growth across the spectrum. And you see that obviously where our marketing dollars have deployed as well, right? We've got Miley Cyrus talking about women's dermatology. We have Jennifer Lopez talking about women's hair loss Rob Gronkowski talking about mental health. So huge belief that this differentiation combo of the brand and the expansion breadth, is creating huge value. And so what I think you can expect from us is that continued expansion every quarter, every two quarters, the launch of new major categories. Ones we've talked about in the past include things like sleep weight management, fertility, hypertension, hyperlipidemia. We believe these categories are incredibly well suited and can be safely treated on the Hims & Hers platform as built today. So I think when you look at that and then you also take a look at the mobile platform that was announced earlier and the introduction of programs in that world on which you can build very catered journeys for very specific new categories, I think it lends itself very naturally to that long-term vision of a broad ecosystem of care options all under this membership. So I think you can expect us to continue to launch those categories toward the end of this year and into Q1, and frankly, expect that to take place on an ongoing basis for the three to five years ahead. Unidentified Analyst: Great, thanks. And then just a follow-up question. You called out last quarter that you were expecting to see some compression in AOVs driven by the recent acquisitions, but it seems like those are the same sequentially. Could you just provide some color on what was driving that performance? Spencer Lee: Yeah. So AOVs came in a little bit stronger than expected and primarily driven by mix shift. I mean I think we had some positive mix shift in the core Hims business that offset some of the AOV compression that we thought that would have happened as a result of our acquisitions. Going forward, in Q4, I think what we're sort of seeing in the business right now is AOVs that will likely be in line with Q3 or slightly down depending on how sort of mix shift plays out on the core Hims business over the next couple of months. But not any material movements, but in line to maybe slightly down in Q4. Unidentified Analyst: Great. Thank you, and congrats again on the quarter. Spencer Lee: Thank you. Operator: For our next question, we have Jessica Tassan from Piper Sandler. Jessica, your line is open. Jessica Tassan: Hi. Thank you for taking the question, and nice quarter. So, I think early in the call Andrew, you highlighted an impressive 88% long-term retention rate. Can you just help us understand what that number is referring to? What does it maybe include or exclude? And what is the long-term timeframe? Thank you. Andrew Dudum: Yes. So what we've disclosed in the past and thank you for your question, is 88% long-term retention and that's total retention between the year two and year three of a lifetime value for one of those consumers. So between year two and two you're retaining 88% of the value of that cohort, which we just think is incredibly indicative of the stickiness of the platform, right? And when you think about the fact that -- I think we disclosed this 94% 95% of our revenue is long-term recurring subscription revenue. It's the fact that what people are signing up with Hims & Hers is a chronic condition, right, a chronic program that helps them treat something that is an ongoing long-term relationship. And so that metric we think is really reflective of the long-term stickiness of the cohorts. And we believe that will really continue to be the case given the types of categories we continue to expand into. Jessica Tassan: Awesome. And then just maybe as a follow-up on the launch of programs. So how are you thinking kind of about pursuing reimbursement alongside developing new clinical programs or expanding into new clinical areas? And then just is there any relationship between the launch of programs and your relationship with Privia Health that I think you guys announced? Andrew Dudum: Yes. There's no direct relationship between the programs launch and Privia Health per se. What is at the core of programs however is, a number of relationships with either health systems or medical specialists that are coming from top universities and top programs where those partnerships are creating and crafting the actual journey and the content that we then are able to produce and bring to market. So each of these programs is being built in partnership with leading specialists and individuals coming from these institutions, for the most part that are helping us drive that value. As we continue to launch those programs, I think like I've shared the majority of offerings will be and continue to be cash pay because we believe that will be built with the verticalized provider group, the verticalized pharmacy the ability to really treat these patients start to finish. We can deliver that at cash pay prices in almost all situations. It's cheaper than most people's co-pays for their insurance, given the acceleration of high deductible plans in the country. But with that said, we are continuing to work on that insurance reimbursement. The team is actively involved in that for very specific conditions and specific categories. And so you can imagine specific programs that do have reimbursement dynamics where the cash pay cost is just not an achievable accessible option. So we do think that will play in and as we continue to expand on programs and introduce categories where reimbursement dynamics are important. Jessica Tassan: All right. Thank you. Andrew Dudum: Thank you. Operator: At this time there are no further questions. I will now turn the call to Andrew Dudum, for closing comments. Andrew Dudum: Awesome. I just want to thank everybody for joining today and thank you all for the great questions. Also just want to thank my team for all the hard work. It has been an incredible quarter and I'm so proud of what has been built and we are very much looking forward to sharing more with all of you soon. So everybody, please have a great day. Operator: Ladies and gentlemen, this concludes today's conference call. Thank you all for participating. You may now disconnect.
Hims & Hers Health, Inc. (NYSE:HIMS) Targets European Expansion with ZAVA Acquisition
- Ryan Macdonald from Needham sets a price target of $65 for NYSE:HIMS, indicating a potential upside of 21.25%.
- The acquisition of ZAVA is expected to expand Hims & Hers' market opportunity by $52 billion.
- HIMS stock experiences a 5.8% increase in premarket trading following the acquisition announcement.
Hims & Hers Health, Inc. (NYSE:HIMS) is a leading telehealth company that offers a wide range of health and wellness services. The company specializes in providing personalized healthcare solutions in areas such as dermatology, weight loss, sexual health, and mental health. Competing with other telehealth giants like Teladoc Health and Amwell, Hims & Hers is keen on expanding its market presence both in the U.S. and internationally.
On June 4, 2025, Ryan Macdonald from Needham set a price target of $65 for NYSE:HIMS, suggesting a potential upside of 21.25% from its current trading price of $53.61. This optimistic outlook is largely due to Hims & Hers' strategic acquisition of ZAVA, a European digital health platform. The acquisition, which is funded entirely in cash, is expected to close in the latter half of 2025, potentially expanding the company's market opportunity by $52 billion.
The acquisition of ZAVA will significantly enhance Hims & Hers' presence in the U.K. and facilitate its entry into Germany, France, and Ireland. ZAVA, which currently serves over 1.3 million active customers and conducted nearly 2.3 million consultations in 2024, will bolster Hims & Hers' international footprint, allowing the company to offer tailored healthcare services across Europe.
Despite the promising expansion, NYSE:HIMS stock has experienced a decline, currently priced at $53.61, reflecting a decrease of 2.05% or $1.12. The stock has fluctuated between a low of $52.80 and a high of $59.29 during the day. Over the past year, it reached a high of $72.98 and a low of $13.47, with a market capitalization of approximately $11.55 billion.
Following the acquisition announcement, NYSE:HIMS stock saw a 5.8% increase in premarket trading, indicating investor optimism. The deal is projected to be accretive by 2026, enhancing Hims & Hers' footprint in Europe and introducing a new, personalized dimension of digital health. The company plans to leverage the ZAVA platform to establish its own branded presence in these markets.
Hims & Hers Health, Inc. (HIMS) Stock Performance and Citigroup's Rating
- Citigroup maintains a "Sell" rating for Hims & Hers Health, Inc. (NYSE:HIMS) despite a 38.6% surge in stock price.
- The stock's performance significantly outpaces both the Zacks S&P 500 composite and the Zacks Medical Info Systems industry.
- HIMS showcases volatility with a current stock price of $56.77 and a market capitalization of approximately $12.23 billion.
Hims & Hers Health, Inc. (NYSE:HIMS) is a telehealth company that provides a range of health and wellness products and services. The company focuses on offering accessible healthcare solutions through its online platform, catering to both men and women. HIMS operates in the competitive telehealth industry, where it faces competition from other digital health companies.
On June 2, 2025, Citigroup maintained its "Sell" rating for HIMS, with the stock priced at approximately $56.76 at the time. Despite this rating, HIMS has seen a remarkable surge in its stock price, increasing by 38.6% over the past month. This performance significantly outpaces the Zacks S&P 500 composite's 6.1% rise and the 16.9% gain in the Zacks Medical Info Systems industry.
The current stock price of HIMS is $56.77, reflecting a slight change of $0.21, or 0.37%. The stock has traded between $55.68 and $58.77 today, showcasing some volatility. Over the past year, HIMS has experienced a high of $72.98 and a low of $13.47, indicating a wide range of price movements.
HIMS has a market capitalization of approximately $12.23 billion, highlighting its significant presence in the telehealth sector. Today's trading volume for HIMS is 34,842,297 shares, suggesting active investor interest. As highlighted by Benzinga, the article "Check Out What Whales Are Doing With HIMS" may provide further insights into the stock's dynamics.
While media reports and rumors can cause immediate price fluctuations, fundamental factors like earnings estimate revisions are crucial for long-term investment decisions. Investors should consider these elements when evaluating HIMS's future trajectory in the telehealth industry.
Hims & Hers Shares Fall 7% on Q1 EPS Miss and Cautious Q2 Forecast Despite Revenue Surge
Hims & Hers Health (NYSE:HIMS) reported first-quarter results that showed impressive revenue growth and subscriber expansion but fell short on earnings, with a softer near-term outlook prompting a 7% drop in shares in pre-market today.
The telehealth company posted adjusted earnings of $0.20 per share for Q1 2025, below the analyst consensus of $0.23. Revenue surged 111% year-over-year to $586 million, beating expectations of $538.9 million, as the company continues to scale its direct-to-consumer healthcare model.
The subscriber base grew 38% from the prior year to reach 2.4 million users. However, gross margin narrowed to 73%, down from 82% in the same quarter last year, reflecting increased costs tied to growth and service expansion.
Looking ahead, Hims & Hers reaffirmed its full-year revenue guidance of $2.3 billion to $2.4 billion, in line with analyst expectations, while raising its adjusted EBITDA forecast to a range of $295 million to $335 million.
However, the Q2 revenue outlook of $530 million to $550 million fell short of the $564.5 million consensus estimate, weighing on investor sentiment. The company expects Q2 adjusted EBITDA between $65 million and $75 million.
Hims & Hers Shares Fall 7% on Q1 EPS Miss and Cautious Q2 Forecast Despite Revenue Surge
Hims & Hers Health (NYSE:HIMS) reported first-quarter results that showed impressive revenue growth and subscriber expansion but fell short on earnings, with a softer near-term outlook prompting a 7% drop in shares in pre-market today.
The telehealth company posted adjusted earnings of $0.20 per share for Q1 2025, below the analyst consensus of $0.23. Revenue surged 111% year-over-year to $586 million, beating expectations of $538.9 million, as the company continues to scale its direct-to-consumer healthcare model.
The subscriber base grew 38% from the prior year to reach 2.4 million users. However, gross margin narrowed to 73%, down from 82% in the same quarter last year, reflecting increased costs tied to growth and service expansion.
Looking ahead, Hims & Hers reaffirmed its full-year revenue guidance of $2.3 billion to $2.4 billion, in line with analyst expectations, while raising its adjusted EBITDA forecast to a range of $295 million to $335 million.
However, the Q2 revenue outlook of $530 million to $550 million fell short of the $564.5 million consensus estimate, weighing on investor sentiment. The company expects Q2 adjusted EBITDA between $65 million and $75 million.
Hims & Hers Health, Inc. (HIMS) Quarterly Earnings and Strategic Partnerships Drive Optimism
- Hims & Hers Health, Inc. (NYSE:HIMS) is set to release its quarterly earnings with an estimated EPS of $0.12 and projected revenue of $538.4 million.
- The company's stock price surged by 23%, closing at $35.04, following the announcement of a partnership with Novo Nordisk to sell the weight-loss drug, Wegovy.
- HIMS showcases a strong financial health with a P/E ratio of 62.84, a price-to-sales ratio of 5.27, and a debt-to-equity ratio of 0.024.
Hims & Hers Health, Inc. (NYSE:HIMS) is a telehealth company that focuses on providing personalized healthcare solutions. The company offers a range of services, including sexual health, dermatology, and mental health, which collectively generated over $1.2 billion in sales in 2024. HIMS is set to release its quarterly earnings on Monday, May 5, 2025, with Wall Street analysts estimating earnings per share (EPS) of $0.12 and projected revenue of approximately $538.4 million.
The MedTech sector, which includes companies like HIMS, is showing promising signs of recovery. As highlighted by Zacks, HIMS, along with GMED, QDRL, and HAE, is expected to surpass Q1 earnings estimates. This positive outlook is attributed to a rebound in base business activities compared to the previous year. Despite ongoing macroeconomic uncertainties, the Medical sector is demonstrating significant earnings growth, outperforming other sectors.
HIMS recently experienced a significant stock price increase of 23%, closing at $35.04 in the last trading session. This surge was driven by a higher-than-average trading volume and the company's announcement of a new partnership to sell Novo Nordisk's weight-loss drug, Wegovy, on its telehealth platform. This collaboration allows U.S. customers to access NovoCare Pharmacy directly through Hims & Hers Health's online platform, offering all dose strengths of Wegovy bundled with a membership for $599 per month.
The partnership with Novo Nordisk helps to de-risk HIMS's investment strategy, although it does not significantly shift the company's primary focus on personalized healthcare solutions. The company had already set a target of $725 million in weight-loss sales for the year, excluding any sales from branded GLP-1 products. HIMS's core business continues to thrive, with substantial contributions from sectors such as sexual health, dermatology, and mental health.
Financially, HIMS has a price-to-earnings (P/E) ratio of approximately 62.84, indicating that investors are willing to pay $62.84 for every dollar of earnings. The company's price-to-sales ratio stands at about 5.27, suggesting that investors are paying $5.27 for every dollar of sales. With a debt-to-equity ratio of about 0.024, HIMS has a relatively low level of debt compared to its equity, and a current ratio of approximately 1.79, indicating a good level of liquidity to cover short-term liabilities.
Hims & Hers Health, Inc. (HIMS) Quarterly Earnings and Strategic Partnerships Drive Optimism
- Hims & Hers Health, Inc. (NYSE:HIMS) is set to release its quarterly earnings with an estimated EPS of $0.12 and projected revenue of $538.4 million.
- The company's stock price surged by 23%, closing at $35.04, following the announcement of a partnership with Novo Nordisk to sell the weight-loss drug, Wegovy.
- HIMS showcases a strong financial health with a P/E ratio of 62.84, a price-to-sales ratio of 5.27, and a debt-to-equity ratio of 0.024.
Hims & Hers Health, Inc. (NYSE:HIMS) is a telehealth company that focuses on providing personalized healthcare solutions. The company offers a range of services, including sexual health, dermatology, and mental health, which collectively generated over $1.2 billion in sales in 2024. HIMS is set to release its quarterly earnings on Monday, May 5, 2025, with Wall Street analysts estimating earnings per share (EPS) of $0.12 and projected revenue of approximately $538.4 million.
The MedTech sector, which includes companies like HIMS, is showing promising signs of recovery. As highlighted by Zacks, HIMS, along with GMED, QDRL, and HAE, is expected to surpass Q1 earnings estimates. This positive outlook is attributed to a rebound in base business activities compared to the previous year. Despite ongoing macroeconomic uncertainties, the Medical sector is demonstrating significant earnings growth, outperforming other sectors.
HIMS recently experienced a significant stock price increase of 23%, closing at $35.04 in the last trading session. This surge was driven by a higher-than-average trading volume and the company's announcement of a new partnership to sell Novo Nordisk's weight-loss drug, Wegovy, on its telehealth platform. This collaboration allows U.S. customers to access NovoCare Pharmacy directly through Hims & Hers Health's online platform, offering all dose strengths of Wegovy bundled with a membership for $599 per month.
The partnership with Novo Nordisk helps to de-risk HIMS's investment strategy, although it does not significantly shift the company's primary focus on personalized healthcare solutions. The company had already set a target of $725 million in weight-loss sales for the year, excluding any sales from branded GLP-1 products. HIMS's core business continues to thrive, with substantial contributions from sectors such as sexual health, dermatology, and mental health.
Financially, HIMS has a price-to-earnings (P/E) ratio of approximately 62.84, indicating that investors are willing to pay $62.84 for every dollar of earnings. The company's price-to-sales ratio stands at about 5.27, suggesting that investors are paying $5.27 for every dollar of sales. With a debt-to-equity ratio of about 0.024, HIMS has a relatively low level of debt compared to its equity, and a current ratio of approximately 1.79, indicating a good level of liquidity to cover short-term liabilities.
BofA Maintains Bearish Stance on Hims & Hers Amid Signs of Slowing Core Growth
BofA Securities reiterated its Underperform rating on Hims & Hers Health (NYSE:HIMS), keeping its price target steady at $22, citing signs of decelerating momentum in the company’s core business. The company’s shares are currently down more than 10% intra-day.
Although online revenue in Q1 appears poised to beat consensus estimates—with projections ranging between $567 million and $601 million versus the $528.4 million expected—March data showed a notable slowdown. Year-over-year sales growth dropped by 45 percentage points to 78%, ending a five-month streak of acceleration.
One area of concern is the average transaction value, which fell month-over-month for the first time since September. BofA also noted a decline in GLP-1 sales in March, possibly due to reduced advertising or a transition to alternative weight loss treatments like personalized liraglutide or oral medications.
The firm now estimates GLP-1s accounted for around 38–40% of Q1 sales, suggesting core growth stands closer to 35% year-over-year—better than earlier estimates, but still a drop from the 39% seen in Q4.
With the company’s 2025 guidance assuming a reacceleration in core growth, BofA questions the achievability of its $725 million weight loss target, especially if semaglutide contributions taper off after Q2. Minor adjustments were made to the firm’s forecasts, but the overall cautious view remains unchanged.
